Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire11/05 22:30

Lyell Immunopharma Names Sumant Ramachandra to Board >LYEL

Dow Jones11/01 04:02

Lyell Immunopharma Expects Its Cash Balance Will Fund Ops Into 2027 >LYEL

Dow Jones11/01 04:02

Press Release: Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Dow Jones11/01 04:00

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

Benzinga10/31 02:31

Lyell Cut to Underperform by BofA, Pipeline Reorganization Cited

Seeking Alpha10/30 21:56